Onyx Pharmaceuticals is developing innovative small molecule cancer treatments based on a molecular understanding of cancer. Our lead product is Nexavar® (sorafenib) tablets, a novel, oral multiple kinase inhibitor that targets proteins involved in both tumor cell proliferation and angiogenesis (the formation of new blood vessels to support cancer cell growth). This product is being developed and marketed in collaboration with Bayer HealthCare Pharmaceuticals.

Nexavar is approved in more than 60 countries for the treatment of patients with advanced kidney cancer. In addition, we were recently granted approval in a second indication, liver cancer, in the U.S. and EU. As part of a broad development program, Nexavar is also currently being evaluated in randomized trials in non-small cell lung cancer, breast cancer, melanoma, and other tumor types. We also have a second product in clinical testing, a small molecule cell cycle inhibitor that resulted from a collaboration with Pfizer, which is responsible for developing the drug.

For questions about Nexavar treatment, reimbursement, and patient support, please call 1-866-NEXAVAR (1-866-639-2827) or 1.87.REACH.4.IT (1.877.322.4448).

LATEST WEBCAST
Bank of America Health Care Conference